Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03771261
Other study ID # Pro00089075
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 15, 2018
Est. completion date November 8, 2021

Study information

Verified date January 2022
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the trial is to assess the effects of combining regular, generous intakes of high quality protein (with substantial amounts provided from whole eggs and egg whites) with calorie restriction on insulin resistance and weight loss (along with function, body composition, racial disparities, and a number of secondary outcomes) in black and white older adults with prediabetes who are participating in a 4-month intervention. The investigators will compare these effects to the same outcomes with a control group consuming a traditional control regimen of calorie restriction over the same duration.


Description:

Older (>60 yrs) men and women (50% African American, 50% white) who are obese (BMI >30 kg/m2) and have pre-diabetes will be randomly assigned (1:1 ratio; couples randomized together) to one to two treatment groups: 1) Weight loss intervention (WL-Control; n = 20): subjects follow a calorie-reduction diet for a weight loss of ≥10%, protein~0.8g/g/d; and 2) High protein weight loss intervention (WL-Protein; n = 20): subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of high quality protein (> 30g protein, 3/day, 60-70% egg protein). Primary (insulin resistance/sensitivity, weight loss) and secondary outcomes (physical function, body composition, diet adherence, cognitive function, readiness to change) will be measured at 0 and 4 months.


Recruitment information / eligibility

Status Completed
Enrollment 99
Est. completion date November 8, 2021
Est. primary completion date November 5, 2021
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - Age > 60 years - Identifies as Caucasian/white or African-American/black - Obese body weight (>30 kg/m2) - Able to speak and understand spoken and written English - Elevated fasting plasma glucose (=95 and <126 mg/dL) - Age-normal Kidney function (= 45 mL/min/1.73 m2) Exclusion Criteria: - Body weight > 224 kg (limit of the BodPod) - Treated or untreated diabetes (prior diagnosis, treatment, or fasting blood glucose =126 mg/dL) - Presence of unstable, acutely symptomatic, or life-limiting illness - Positive screen for dementia using Mini-Cog evaluation tool - Neurological conditions causing functional or cognitive impairments - History of significant weight instability (defined as > 10 pounds weight gain or loss over 6 months prior to study participation) - Allergy or intolerance to egg products - Unwillingness or inability to be randomized to any one of two intervention groups, submit to all study testing, or continuously participate in a randomly assigned lifestyle intervention program for four months - Inability to walk independently - Unable to give consent - Unable to complete written recording forms including journals of eating and exercise behaviors. - Current use of the following medications: monoamine oxidase inhibitors, prescription weight loss medications, insulin, metformin or any other hypoglycemic agent - Primary Care Physician advises against participation - Smoker - Unusually or unstable renal function

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Weight Loss
Participants will be prescribed hypo-caloric diet by a registered dietitian and attend weekly social support/nutrition education meetings.
Dietary Supplement:
Egg Protein
Participants will be provided pre-packaged hard-boiled eggs (3/day, medium) and egg white protein powder.

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Duke University Egg Nutrition Center

Country where clinical trial is conducted

United States, 

References & Publications (3)

Porter Starr KN, McDonald SR, Bales CW. Obesity and physical frailty in older adults: a scoping review of lifestyle intervention trials. J Am Med Dir Assoc. 2014 Apr;15(4):240-50. doi: 10.1016/j.jamda.2013.11.008. Epub 2014 Jan 17. — View Citation

Porter Starr KN, McDonald SR, Weidner JA, Bales CW. Challenges in the Management of Geriatric Obesity in High Risk Populations. Nutrients. 2016 May 4;8(5):262. doi: 10.3390/nu8050262. — View Citation

Porter Starr KN, Pieper CF, Orenduff MC, McDonald SR, McClure LB, Zhou R, Payne ME, Bales CW. Improved Function With Enhanced Protein Intake per Meal: A Pilot Study of Weight Reduction in Frail, Obese Older Adults. J Gerontol A Biol Sci Med Sci. 2016 Oct;71(10):1369-75. doi: 10.1093/gerona/glv210. Epub 2016 Jan 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Insulin Resistance at 4 months Blood glucose and insulin levels in whole blood will be used to compute HOMA-IR (= glucose mg/dL x insulin mg/dL/405) 0 to 4 months
Primary Change from Baseline Body weight at 4 months Weight loss as measured in light clothing on a dedicated scale. 0 to 4 months
Secondary Change from baseline Short Physical Performance Battery at 4 months Physical Performance as measured by Short Physical Performance Battery (SPPB) 0 to 4 months
Secondary Change from baseline 6-minute walk (meters) at 4 months Distance (meters) walked in 6 minutes 0 to 4 months
Secondary Change from baseline 8-foot up and Go time at 4 months Time it takes to get up from a chair walk around a cone and sit back down (8-foot up and go) 0 to 4 months
Secondary Change from baseline 30-second chair stands (number of stands) at 4 months the number of chair stands completed in 30 seconds 0 to 4 months
Secondary Change from baseline handgrip strength at 4 months the highest weight achieved from 2 attempts using the JAMAR dynamometer 0 to 4 months
Secondary Change from baseline grooved pegboard time at 4 months measure of hand dexterity, time it takes to fit pegs into grooved pegboard 0 to 4 months
Secondary Change from baseline fat mass (%) at 4 months Body fat mass (%) as measured by Bodpod 0 to 4 months
Secondary Change from baseline fat mass (kgs) at 4 months Body fat mass (kg) as measured by Bodpod 0 to 4 months
Secondary Change from baseline lean mass (kgs) at 4 months Body lean mass (kg) as measured by Bodpod 0 to 4 months
Secondary Change from baseline lean mass (%) at 4 months Body lean mass (%) as measured by Bodpod 0 to 4 months
Secondary Change from baseline minimal waist circumference at 4 months Body proportions will be measured at the minimal waist using a Gulick II tape measure with the tape placed directly on the skin (not over the clothing). Measurements will be taken once at each location before completing a second measurement, and an average of the two will be recorded. A third measurement will be taken if the first two measurements are > 0.5 cm. 0 to 4 months
Secondary Change from baseline umbilical waist circumference at 4 months Body proportions will be measured at the umbilical waist using a Gulick II tape measure with the tape placed directly on the skin (not over the clothing). Measurements will be taken once at each location before completing a second measurement, and an average of the two will be recorded. A third measurement will be taken if the first two measurements are > 0.5 cm. 0 to 4 months
Secondary Change from baseline hip circumference at 4 months Body proportions will be measured at the hip using a Gulick II tape measure with the tape placed directly on the skin (not over the clothing). Measurements will be taken once at each location before completing a second measurement, and an average of the two will be recorded. A third measurement will be taken if the first two measurements are > 0.5 cm. 0 to 4 months
Secondary Change from baseline total calories at 4 months Total calories will be measured using 3-day food records (participants record everything they eat and drink for three days) 0 to 4 months
Secondary Change from baseline macronutrient intake at 4 months Macronutrient intake will be measured using 3-day food records (participants record everything they eat and drink for three days) 0 to 4 months
Secondary Change from baseline micronutrient intake at 4 months Micronutrient intake will be measured using 3-day food records (participants record everything they eat and drink for three days) 0 to 4 months
Secondary Change from baseline Symbol digit modalities test at 4 months Symbol Digit Modalities Test measures cognitive impairment 0 to 4 months
Secondary Change from baseline Trail Making Test at 4 months Trail Making Test neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy. 0 to 4 months
Secondary Change from baseline Hopkins Verbal Learning Test at 4 months Hopkins Verbal Learning Test consists of three trials of free-recall of a 12-item, semantically categorized list, followed by yes/no recognition. 0 to 4 months
Secondary Change from baseline Profile of Mood States at 4 months Profile of Mood States is a psychological rating scale used to assess transient, distinct mood states that uses a five-point scale ranging from "not at all" to "extremely". 0 to 4 months
Secondary Change from baseline Perceived Stress Scale at 4 months Perceived Stress Scale is a a 12-item stress assessment instrument. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. 0 to 4 months
Secondary Change from Baseline Insulin Sensitivity at 4 months insulin sensitivity HOMA-ß (= 360 x insulin mg/dL / glucose mg/dL - 63; %). 0 to 4 months
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2